Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in older patients with uHCC
Among older patients with uHCC, the combination therapy demonstrated higher ORR and longer PFS and OS, although it had higher incidences of AEs and drug withdrawal.
Authors
- Yangxun Pan (ORCID: https://orcid.org/0000-0002-3887-5852)
- Jiabei Wang (ORCID: https://orcid.org/0000-0002-4578-3817)
- Hui‐Chuan Sun (ORCID: https://orcid.org/0000-0003-3761-7058)
- Lianxin Liu (ORCID: https://orcid.org/0000-0002-3535-6467)
- Chuangye Han (ORCID: https://orcid.org/0000-0002-7670-4763)
- Jian‐Hong Zhong (ORCID: https://orcid.org/0000-0002-1494-6396)
- Li Xu (ORCID: https://orcid.org/0000-0003-4405-1048)
- Yongyi Zeng (ORCID: https://orcid.org/0000-0001-8823-698X)
- Nan-Ya Wang
- Tao Peng
- Ledu Zhou (ORCID: https://orcid.org/0000-0003-0702-0429)
- Li Yu (ORCID: https://orcid.org/0000-0002-2221-8911)
- Kuan Hu (ORCID: https://orcid.org/0000-0002-8698-1369)
- Hongzhi Liu (ORCID: https://orcid.org/0000-0001-6216-0796)
- Xiaodong Zhu (ORCID: https://orcid.org/0000-0002-7997-8268)
Institutions
- Fujian Medical University (CN)
- Central South University (CN)
- Guangxi Medical University (CN)
- Fudan University (CN)
- Mengchao Hepatobiliary Hospital (CN)
- First Affiliated Hospital of GuangXi Medical University (CN)
- Zhongshan Hospital (CN)
- Xiangya Hospital Central South University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-04-28
- DOI
- https://doi.org/10.3389/fonc.2025.1515640
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00